Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04936724
Other study ID # UPCC 04021
Secondary ID U54CA22997384370
Status Completed
Phase N/A
First received
Last updated
Start date December 22, 2020
Est. completion date November 19, 2021

Study information

Verified date April 2024
Source Abramson Cancer Center at Penn Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.


Description:

This laboratory-based study will aim to enroll 120 current cigarette users to complete a 1-day randomized, parallel design protocol. The participants will be randomized to one of two conditions, pictorial warning labels (PWLs) with well-known or lesser-known tobacco harms. After completing a baseline questionnaire, the participants will view 4 warning labels from the assigned group and complete a follow-up questionnaire. Eye-tracking will provide data on visual processing of the warning labels and the effect of these labels on knowledge, attitudes, and beliefs about smoking will be supplemented by self-report.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date November 19, 2021
Est. primary completion date November 19, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Current cigarette smokers using only filtered commercially manufactured cigarettes; smoking at least 5 cigarettes daily and smoking for at least last 1 year. - Participants must physically present a pack of their preferred brand of cigarettes at the lab session to confirm their status as a cigarette smoker. - Not currently undergoing smoking cessation treatment or planning to quit smoking currently or in the next month. - Plan to live in the area for the duration of the study. - Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined Informed Consent and HIPAA form. - Able to communicate fluently in English (i.e., speaking, writing, and reading) as determined by the research assistant. Exclusion Criteria: - Use of any nicotine-containing products other than cigarettes. Participants reporting isolated use of other nicotine-containing products less than 5 times per month are eligible to participate. - Not actively trying to quit smoking currently and had not made a quit attempt in the past month. - Self-report current alcohol consumption that exceeds 25 standard drinks/week. - Self-report current pregnancy or breastfeeding. - Any self-reported impairment - visual (colorblindness or impairments such as glass eye), physical, and/or neurological impairments preventing the proper completion of the study procedures. - Serious or unstable medical condition. - Lifetime history of schizophrenia, psychosis, and/or bipolar disorder. - Current use or discontinuation of anti-psychotic medications within the last 6 months. - Current diagnosis of active major depression. Participants who maintain a diagnosis of major depression who have not experienced any major depressive episodes in the past 6 months and are stable on antidepressant medication(s) are eligible to participate. - Inability to provide informed consent or complete any of the study tasks as determined by the principal investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pictorial Warning Labels
Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.

Locations

Country Name City State
United States Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attention: Latency (Time Until First Fixation) for Image We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Attention: Latency (Time Until First Fixation) for Text We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Attention: Latency Duration (Time of Fixation) for Image We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Attention: Latency Duration (Time of Fixation) for Text We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Attention: Total Fixation Time for Image We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Attention: Total Fixation Time for Text We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition. Day 1
Primary Recall: Participants Ability to Recall Condition Image Participants will view 11 warning label images and would be required to identify the warning label images they saw during their eye tracking portion of the session. This outcome measure (Recall -Image) was assessed in a percentage unit of measure. The percentages are not whole numbers for these items because it's the mean % correct for the condition, or the average percent correct across the four images for the group. The results in the Outcome Measure Data table demonstrate the percentage of participants who correctly identified the images from their condition (4 of the 11 images presented to participants were from their randomized condition; A or B). Day 1
Primary Recall: Participants Ability to Recall Condition Text Participants will view 11 warning label text statements and would be required to identify the warning label text statements they saw during their eye tracking portion of the session. This outcome measure (Recall -Text) was assessed in a percentage unit of measure. The percentages are not whole numbers for these items because it's the mean % correct for the condition, or the average percent correct across the four images for the group. The results in the Outcome Measure Data table demonstrate the percentage of participants who correctly identified the text statements from their condition (4 of the 11 images presented to participants were from their randomized condition; A or B). Day 1
Primary Knowledge of Smoking Harms All participants will select harms caused by tobacco from a list of health issues and diseases, before as well as after viewing the warning labels on the screen. Pre and post warning label exposure knowledge of smoking harms were assessed by using an exploratory scale that asked participants if cigarette smoking caused a list of 18 health conditions with a 5-point response scale, (1=definitely yes 2= probably yes, 3 = might or might not, 4 = probably not, 5 = definitely not). Day 1
See also
  Status Clinical Trial Phase
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Recruiting NCT03802019 - Cigarette Packaging of Low Nicotine Cigarettes N/A
Completed NCT03194256 - Evaluating New Nicotine Standards for Cigarettes - Project 3 N/A
Completed NCT04808609 - Smoking Cessation Pilot for People Living With HIV (PLWH) N/A
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Recruiting NCT03721822 - Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation Phase 1
Completed NCT05162820 - Impact of Solarplast® on Immunity in Active Smokers and Non-smokers N/A
Recruiting NCT03630614 - Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. Phase 3
Completed NCT03502200 - Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures N/A
Completed NCT05473585 - Impact of New Standards for Tobacco Products Among Dual E-Cigarette/Combusted Cigarette Users - Project 2 N/A
Completed NCT04115176 - GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis
Completed NCT04161144 - Enhancing Self Regulation Among Smokers Phase 2
Completed NCT03364751 - Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome N/A
Recruiting NCT05973981 - The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment N/A
Recruiting NCT06190860 - Platelet Rich Fibrin Treatment for the Alveolar Ridge Preservation in Smokers N/A
Recruiting NCT03814434 - Surgical Treatment of Periimplantitis in Patients With Risk Factors N/A
Completed NCT03569748 - Heated Tobacco Products vs Electronic Cigarettes N/A
Completed NCT03500965 - Pictorial Warning Labels and Memory for Relative and Absolute Cigarette Health-risk Information Over Time in Teens N/A
Completed NCT03642041 - Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients